

Minerva Neurosciences, Inc.
Form 3
June 30, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | |
|---|---|--|--|---|---|
| <p>1. Name and Address of Reporting Person *</p> <p>Â Ollier Michele</p> <p>(Last) (First) (Middle)</p> <p>C/O MINERVA NEUROSCIENCES, INC.,Â 245 FIRST STREET SUITE 1800</p> <p>(Street)</p> <p>CAMBRIDGE,Â MAÂ 02142</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>06/30/2014</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Minerva Neurosciences, Inc. [NERV]</p> | <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> | <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p> |
|---|---|--|--|---|---|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
| Common Stock | 3,436,898 | I | See Footnotes <u>(1)</u> <u>(2)</u> <u>(3)</u> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|---|---|--|
|---|---|--|---|---|--|

Edgar Filing: Minerva Neurosciences, Inc. - Form 3

| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) | |
|------------------------------|------------------|-----------------|--------------|----------------------------|----------|---------------------------------------|-----------------------|
| Convertible Promissory Notes | Â (4) | Â (4) | Common Stock | 113,891 | \$ (4) | I | See Footnotes (1) (5) |
| Convertible Promissory Notes | Â (4) | Â (4) | Common Stock | 61,913 | \$ (4) | I | See Footnotes (1) (6) |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Ollier Michele C/O MINERVA NEUROSCIENCES, INC. 245 FIRST STREET SUITE 1800 CAMBRIDGE, MA 02142 | Â X | Â X | Â | Â |

Signatures

/s/ Michele Ollier 06/30/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Michele Ollier, Director of the Issuer, is a partner of of the Index Venture group which provides advisory services to Index Ventures III (Jersey), L.P. ("IVIII Jersey"), Index Ventures III (Delaware), L.P. ("IVIII Delaware"), Index Ventures III Parallel Entrepreneur Fund (Jersey) ("IVPEF III"), Index Ventures IV (Jersey) L.P. ("IVIV Jersey"), Index Ventures IV Parallel Entrepreneur Fund (Jersey) L.P. ("IVPEF IV"), Index Ventures V Parallel Entrepreneur Fund (Jersey), L.P. ("IVPEF V"), Index Ventures V (Jersey), L.P. ("IVV Jersey") and Yucca (Jersey) SLP ("Yucca"). Dr. Ollier disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of her proportionate pecuniary interest therein.
- (2) IVIII Jersey is the direct beneficial owner of 639,257 shares of common stock, IVIII Delaware is the direct beneficial owner of 1,298,582 shares of common stock and IVPEF III is the direct beneficial owner of 23,134 shares of common stock. Index Venture Associates III Limited is the general partner of IVIII Jersey, IVIII Delaware and IVPEF III. Yucca is Administrator of the Index Co-Investment Scheme, collectively, "Index III." IVIV Jersey is the direct beneficial owner of 885,030 shares of common stock and IPEV IV is the direct beneficial owner of 84,008 shares of common stock. Index Venture Associates IV Limited is the general partner of IVIV Jersey and IVPEF IV, collectively, "Index IV."
- (3) IPEV V is the direct beneficial owner of 3,708 shares of common stock and IVV Jersey is the direct beneficial owner of 457,638 shares of common stock. Index Venture Associates V Limited is the general partner of IPEV V and IVV Jersey, collectively, "Index V." Yucca is the direct beneficial owner of 45,541 shares of common stock. Index III, Index IV, Index V and Yucca (collectively, the "Index Entities") are members of a "group" for purposes of Section 13(d) of the Exchange Act. This Statement Form 3 is being filed jointly by the Index Entities in connection with the effectiveness of the Issuer's Registration Statement on Form S-1 (File No. 333-195169). Each of the Index Entities disclaims beneficial ownership of the securities held of record by any of the other Index Entities, except, in each case, to the extent of their respective proportionate pecuniary interest(s) therein.
- (4) The outstanding principal and accrued and unpaid interest on the convertible promissory notes shall automatically convert upon the closing of the issuer's initial public offering into a number of shares of common stock equal to the quotient of the aggregate outstanding principal amount and all accrued and unpaid interest due under the notes divided by the initial public offering price, which is currently assumed to be \$6.00 per share.

Edgar Filing: Minerva Neurosciences, Inc. - Form 3

- Consists of notes with a principal balance of \$210,198.30 and interest accrued through June 30, 2014 of \$10,780.58 convertible into 36,380 shares of Common Stock held by IVIII Jersey; notes with a principal balance of \$426,995.40 and interest accrued through June 30, 2014 of \$21,899.60 convertible into 74,816 shares of Common Stock held by IVIII Delaware; notes with a principal balance of \$7,606.30 and interest accrued through June 30, 2014 of \$390.11 convertible into 1,333 shares of Common Stock held by IVPEF III; and notes with a principal balance of \$5,200 and interest accrued through June 30, 2014 of \$266.70 convertible into 912 shares held by Yucca.
- (5)

- Consists of notes with a principal balance of Euro 234,888.88 (\$320,130.05, as converted) and interest accrued through June 30, 2014 of Euro 12,046.89 (\$16,418.71, as converted) convertible into 56,092 shares of Common Stock held by IVIV Jersey; notes with a principal balance of Euro 22,296.30 (\$30,387.63, as converted) and interest accrued through June 30, 2014 of Euro 1,143.52 (\$1,558.51, as converted) convertible into 5,325 shares of Common Stock held by IVPEF IV; and notes with a principal balance of Euro 2,074.07 (\$2,826.75, as converted) and interest accrued through June 30, 2014 of Euro 106.38 (\$144.98, as converted) convertible into 496 shares of common stock held by Yucca acting through Ogier Employee Benefit Services Limited. All amounts converted from Euro into U.S. Dollars (\$) applied the conversion rate from the Euro as of June 25, 2014, which was 1.3629.
- (6)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.